A new study from Bangladesh shows that the hepatitis E vaccine Hecolin provides long-lasting protection for women of childbearing age. The research followed 1,480 women aged 16 to 39 for up to 35 months. Those who received the vaccine had a significantly higher rate of immunity compared to women who got a hepatitis B vaccine. Specifically, 83.7% of vaccinated women remained seropositive versus 51.6% in the control group. The vaccine also triggered a strong cellular memory response, which suggests the body can fight off the virus for a long time.
The study was conducted in Matlab, Bangladesh, a region where hepatitis E is common. The virus can be especially dangerous for pregnant women, so protecting this group is important. The researchers measured both antibody levels and immune cell responses. They found that vaccinated women had a different pattern of antibody subtypes, which may indicate a more robust and lasting immune response.
One limitation of the study is that the interpretation of some immune cell data was limited because not enough cells were recovered from blood samples. This means the findings on cellular memory should be taken with some caution. No safety concerns were reported in the study.
Overall, this research offers valuable evidence that the hepatitis E vaccine can provide durable protection for women in endemic areas. It supports the use of Hecolin to prevent hepatitis E in regions where the virus is a serious health threat.